DaVita (NYSE:DVA) Posts Earnings Results, Beats Estimates By $0.43 EPS

DaVita (NYSE:DVA) posted its earnings results on Thursday. The company reported $2.38 earnings per share for the quarter, beating the consensus estimate of $1.95 by $0.43, RTT News reports. The firm had revenue of $3.07 billion during the quarter, compared to the consensus estimate of $3.03 billion. DaVita had a net margin of 6.61% and a return on equity of 66.59%. The firm’s revenue for the quarter was up 6.9% on a year-over-year basis. During the same period last year, the firm posted $1.58 EPS. DaVita updated its FY24 guidance to $9.00-$9.80 EPS.

DaVita Price Performance

Shares of NYSE DVA traded down $7.79 during midday trading on Friday, reaching $134.45. The company’s stock had a trading volume of 2,541,405 shares, compared to its average volume of 628,593. The company has a market cap of $11.79 billion, a P/E ratio of 15.28, a P/E/G ratio of 1.27 and a beta of 1.04. The company has a debt-to-equity ratio of 6.65, a quick ratio of 1.13 and a current ratio of 1.19. DaVita has a fifty-two week low of $71.51 and a fifty-two week high of $145.04. The business’s 50 day moving average price is $133.71 and its two-hundred day moving average price is $112.59.

Wall Street Analyst Weigh In

DVA has been the topic of several research analyst reports. StockNews.com raised shares of DaVita from a “buy” rating to a “strong-buy” rating in a research report on Thursday, April 25th. TheStreet raised DaVita from a “c+” rating to a “b-” rating in a report on Wednesday, February 7th. Truist Financial raised their price objective on shares of DaVita from $130.00 to $135.00 and gave the company a “hold” rating in a research note on Tuesday, February 20th. Barclays began coverage on shares of DaVita in a report on Wednesday, March 6th. They issued an “equal weight” rating and a $133.00 price target for the company. Finally, UBS Group increased their target price on DaVita from $113.00 to $134.00 and gave the company a “buy” rating in a report on Wednesday, February 14th. Two investment analysts have rated the stock with a hold rating, one has given a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $118.50.

Insider Buying and Selling at DaVita

In other DaVita news, insider James O. Hearty sold 26,164 shares of the business’s stock in a transaction that occurred on Friday, February 16th. The shares were sold at an average price of $119.64, for a total transaction of $3,130,260.96. Following the sale, the insider now directly owns 20,264 shares of the company’s stock, valued at approximately $2,424,384.96. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. In other DaVita news, CEO Javier Rodriguez sold 67,603 shares of the stock in a transaction that occurred on Monday, February 26th. The stock was sold at an average price of $126.11, for a total value of $8,525,414.33. Following the transaction, the chief executive officer now owns 488,697 shares in the company, valued at $61,629,578.67. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, insider James O. Hearty sold 26,164 shares of the stock in a transaction that occurred on Friday, February 16th. The stock was sold at an average price of $119.64, for a total value of $3,130,260.96. Following the completion of the sale, the insider now directly owns 20,264 shares of the company’s stock, valued at $2,424,384.96. The disclosure for this sale can be found here. In the last quarter, insiders have sold 134,540 shares of company stock valued at $16,551,071. 1.40% of the stock is currently owned by corporate insiders.

DaVita Company Profile

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.